{"brief_title": "OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer", "brief_summary": "The purpose of this study is to determine if OSI-774 will improve overall survival of patients with incurable stage IIIB/IV non-small cell lung cancer compared to standard of care. OSI-774 is a new type of drug under evaluation called an epidermal growth factor receptor (EGFR). OSI-774 is an investigational drug that has not yet been approved by the U.S. Food and Drug Administration (FDA).", "condition": "Carcinoma, Non-small-cell Lung", "intervention_type": "Drug", "intervention_name": "Tarceva (erlotinib HCl, OSI-774 )", "criteria": "- Clinical diagnosis of stage IIIB or IV non-small cell lung cancer. - Must have evidence of disease (clinical or radiological). - Have failed 1 but no more than 2 prior chemotherapy regimens, have recovered from any side effects and have not had any chemotherapy for at least 21 days. - If the patient has had surgery, the surgery was at least 2 weeks ago. - Patients whose cancer has spread to their brain or central nervous system are eligible, providing that they have been on stable dose of steroids for at least 4 weeks and are free of symptoms. - If the patient received radiation therapy, treatment was at least 4 weeks ago.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00036647.xml"}